Shine-On BioMedical Co (ROCO:6926) Beginning Cash Position: NT$49.17 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6926 Shine-On BioMedical Co Ltd ROCO:6926
12 GF Score
Price NT$63.00
! 1 Warning Sign
View Full Analysis

What is Shine-On BioMedical Co Beginning Cash Position?

Shine-On BioMedical Co ROCO:6926 12 Beginning Cash Position is NT$49.17 Mil as of Jun. 2026. GuruFocus rates ROCO:6926 with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Shine-On BioMedical Co's Beginning Cash Position for the quarter that ended in Jun. 2026 was NT$49.17 Mil.

Shine-On BioMedical Co's quarterly Beginning Cash Position declined from Jun. 2025 (NT$44.66 Mil) to Dec. 2025 (NT$20.63 Mil) but then increased from Dec. 2025 (NT$20.63 Mil) to Jun. 2026 (NT$49.17 Mil).

Shine-On BioMedical Co's annual Beginning Cash Position declined from Dec. 2023 (NT$373.16 Mil) to Dec. 2024 (NT$102.02 Mil) and declined from Dec. 2024 (NT$102.02 Mil) to Dec. 2025 (NT$44.66 Mil).

Shine-On BioMedical Co Beginning Cash Position Related Terms

Shine-On BioMedical Co Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Shine-On BioMedical Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shine-On BioMedical Co Beginning Cash Position Chart

Shine-On BioMedical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 0.00 824.98 373.16 102.02 44.66

Shine-On BioMedical Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 102.02 42.26 44.66 20.63 49.17
ROCO:6926
12GF Score
Shine-On BioMedical Co Ltd ROCO:6926
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shine-On BioMedical Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of NT$49.17 Mil mean?
Shine-On BioMedical Co (ROCO:6926) has a Beginning Cash Position of NT$49.17 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Shine-On BioMedical Co and its competitors.
Is Shine-On BioMedical Co's Beginning Cash Position too high?
Shine-On BioMedical Co's current Beginning Cash Position is NT$49.17 Mil. Overall, Shine-On BioMedical Co has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Shine-On BioMedical Co's Beginning Cash Position compare to VRTX and REGN?
Shine-On BioMedical Co's Beginning Cash Position of NT$49.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Shine-On BioMedical Co and its competitors. Shine-On BioMedical Co's current Beginning Cash Position is NT$49.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shine-On BioMedical Co stock overvalued right now?
Shine-On BioMedical Co (ROCO:6926) has a current Beginning Cash Position of NT$49.17 Mil. The current Beginning Cash Position is NT$49.17 Mil. Shine-On BioMedical Co's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Shine-On BioMedical Co (ROCO:6926), the current Beginning Cash Position is NT$49.17 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shine-On BioMedical Co Business Description

Address No. 573, Taiwan Boulevard, 10th Floor, Section 2, West District, Taichung, TWN
Shine-On BioMedical Co Ltd develops drugs based on antibodies and nucleic acids. The Company researches, develops, manufactures, and distributes antibody anticancer drugs, nucleic acid anticancer drugs. The company's drug development and nucleic acid therapeutics are focused on providing patients with effective cancer treatment options.
12GF Score

Get the complete analysis for ROCO:6926

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$63.00
Price